Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

DOI Web Site Web Site 4 Citations
  • Ahmed Sawas
    Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, 51 West 51st – Suite 200, New York, NY 10019, USA
  • Dejan Radeski
    Western Diagnostic Pathology & Joondalup Health Campus, 60 Shenton Avenue, Joondalup, Western Australia, Australia
  • Owen A. O’Connor
    Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, USA

Search this article

Description

<jats:p> Peripheral T-cell lymphoma (PTCL) is a disease with poor prognosis and limited treatment options. Recent advances in cancer biology suggest that PTCL may be characterized by gross epigenetic dysregulation, which may help explain its sensitivity to histone deacetylase (HDAC) inhibitors. HDAC inhibitors have demonstrated significant activity in T-cell neoplasms and recently, the BELIEF trial evaluated belinostat leading to its approval in the US. This review discusses the development of belinostat, its mechanism of action, pivotal clinical trials, drug toxicity and its recent approval for patients with relapsed or refractory PTCL. Key clinical trials covered include phase I/II evaluation of belinostat in hematologic malignancies, cutaneous T-cell lymphoma (CTCL) and PTCL. In addition, the BELIEF trial in PTCL leading to FDA approval of belinostat is reviewed in detail. </jats:p>

Journal

Citations (4)*help

See more

Report a problem

Back to top